Table 4 Summary of included studies for GCK-related hyperglycemia
From: Precision treatment of beta-cell monogenic diabetes: a systematic review
Study ID | Number of participants | Sex (M/F) | Baseline group, therapy | Comparison therapy | Mean or median Pre-HbA1c (%) | Mean or median Post-HbA1c (%) | Mean, median, or minimal interval between pre/post HbA1c (months) |
|---|---|---|---|---|---|---|---|
Cohort studies or case series | |||||||
Carlsson et al.21 | 29 | 17/12 | 20 None 7 Insulin 2 Metformin | 29 None | 6.3 | 6.2 | 64 |
Delvecchio et al.22 | 136 | NR | 133 None 2 Insulin 1 Insulin + metformin | 133 None 2 Insulin 1 lost to follow-up | 6.4 | 6.2 | 6 |
Shepherd et al.23 | 8 | NR | 7 Insulin 1 Metformin | 8 No | 6.6 | 6.6 | 15 |
Stride et al. 24 | 18 10 | NR NR | None Insulin | None None | 6.4 6.5 | 6.4 6.3 | 3 3 |
6 | NR | Oral Hypoglycemic agents | None | 6.4 | 6.3 | 3 | |
Cross-sectional studies (uncontrolled group comparisons) | |||||||
Stride et al.24 | 799 | NR | Insulin therapy (n = 60) Median HbA1c (%) 6.3 [6.0, 6.6] | Oral hypoglycemic agent therapy (n = 108) Median HbA1c (%) 6.5 [6.1, 6.9] | No pharmacologic therapy (n = 631) Median HbA1c (%) 6.4 [6.1, 6.7] | ||
